BA
The Boeing Company
BA offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
JCI
Johnson Controls International plc
JCI has the edge over BA overall, supported by stronger valuation and lower modeled downside.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
JCI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
JCI's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA has the edge over JCI in the historical PE scenario, which offers more potential upside but is not a forecast.
JCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 20x | $95.28 | -33% |
| Forward | 22x | $143 | — |
| Fair | 30x | $139 | -2.7% |
| Current | 31x | $143 | — |
| Expensive | 36x | $169 | +18% |
Historical ranges are pointers, not guarantees.
JCI's PE is in its fair range at 31x. If earnings grow as analysts expect, today's price would be 22x next year's earnings, in its cheap range.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
JCI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for JCI, with profitability improving.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has returned to profit: it earned $9.66 per share over the past year, after losing money the year before.
JCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.34 | +36% |
| Q3 2026 | $4.67 | -7.2% |
| Q2 2026 | $5.68 | +70% |
| Q1 2026 | $5.53 | +48% |
| Q4 2025 | $5.25 | +102% |
| Q3 2025 | $5.03 | +100% |
| Q2 2025 | $3.35 | +40% |
| Q1 2025 | $3.73 | +51% |
| Q4 2024 | $2.60 | -15% |
JCI has the edge over BA on earnings, with more consistent year-over-year improvement.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over JCI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA's operating margin was 1.5% last quarter, up 22 points from the same quarter a year ago.
JCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.1B | +10% |
| Q2 2026 | $6.6B | +9.3% |
| Q1 2026 | $6.1B | +8.2% |
| Q4 2025 | $5.8B | +6.8% |
| Q3 2025 | $6.4B | +120% |
| Q2 2025 | $6.1B | -16% |
| Q1 2025 | $5.7B | -15% |
| Q4 2024 | $5.4B | -11% |
JCI's revenue has grown year over year for five quarters in a row: $7.1B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +9.4 points |
| Q2 2026 | 15% | +3.3 points |
| Q1 2026 | 12% | +3.2 points |
| Q4 2025 | 12% | +4.7 points |
| Q3 2025 | 5.5% | -1.4 points |
| Q2 2025 | 12% | -6 points |
| Q1 2025 | 8.8% | +14 points |
| Q4 2024 | 7.5% | +0.9 points |
JCI has the edge over BA on profitability, with a higher operating margin.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA's free cash flow has turned positive after six years mostly in the red: $16M over the past year.
JCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +29% |
| Q2 2026 | $1.5B | +117% |
| Q1 2026 | $604M | +32% |
| Q4 2025 | $531M | +299% |
| Q3 2025 | $838M | +1.5% |
| Q2 2025 | $693M | -25% |
| Q1 2025 | $456M | +$792M |
| Q4 2024 | $133M | +$471M |
JCI generated $3.7B in free cash flow over the past year, up 75% from the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
JCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -2M shares |
| 1 year | -6.6% | -43.1M shares |
| 3 years | -11% | -76.4M shares |
| 5 years | -15% | -110M shares |
| Available history | -21% | -163M shares |
JCI has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $655M |
| Q2 2026 | $264M |
| Q1 2026 | $215M |
| Q4 2025 | — |
| Q3 2025 | $5B |
| Q2 2025 | $310M |
| Q1 2025 | $330M |
| Q4 2024 | $330M |
JCI spent $1.1B buying back its own shares over the past year, down 81% from the year before.
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
JCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 3.0x | Moderate |
| Q3 2025 | 3.4x | Elevated |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 3.8x | Elevated |
JCI has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
JCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 35.5 | Neutral |
JCI's weekly RSI is 50 (neutral) and its Stochastic is 35 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA has the edge over JCI on valuation relative to its sector.
JCI PE vs Industrials Sector
| Metric | JCI | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 24x | 27% above |
| PE % | 56 | 58 | 2 pts below |
JCI is trading at 31x earnings, a 27% premium to the Industrials sector's median of 24x.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
JCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $147.5 | 3.3% below |
| 20 week MA | $145.8 | 2.2% below |
| 50 week MA | $137.7 | 3.5% above |
| 100 week MA | $117.3 | 22% above |
| 200 week MA | $90.8 | 57% above |
JCI has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
JCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.1 | $45.9 | +12% |
| 2021 | $45.9 | $78.1 | +70% |
| 2022 | $78.1 | $64.1 | -18% |
| 2023 | $64.1 | $57.6 | -10% |
| 2024 | $57.6 | $79.8 | +38% |
| 2025 | $79.8 | $122.1 | +53% |
| 2026 YTD | $122.1 | $142.6 | +17% |
JCI has the edge over BA on returns for 2026, with the stronger performance.